PMI Reports Strong Performance for H1: IQOS ZYN Exceeding Expectations

PMI by 2FIRSTS.ai
Apr.24.2024
PMI Reports Strong Performance for H1: IQOS ZYN Exceeding Expectations
PMI announced strong first-quarter performance with a net income of $8.8 billion, driven by smoke-free products.

According to a report on the official website of Philip Morris International (PMI), the company announced its first quarter performance for 2024 on April 24th. The total net revenue was $8.8 billion, an increase of 9.7% from the previous year, exceeding the expected $8.468 billion; gross profit reached $5.6 billion, a 12.4% increase from the previous year, driven by strong performance in smoke-free products. Operating income was $3 billion, an 11.5% increase from the previous year, with organic growth of 22.2%. Highlights of the report include:

 

  • Reported diluted earnings per share of $1.38, a 7.8% increase from the previous year, falling below the expected $1.41. 
  • Adjusted diluted earnings per share were $1.50, an 8.7% growth, excluding currency effects it translates to $1.70, surpassing quarterly expectations. 
  • Revenue from smoke-free products accounted for 39% of total net revenue, with a 21.1% growth in this segment. 
  • A regular quarterly dividend of $1.30 per share was declared, maintaining an annualized dividend of $5.20 per share. 

 

PMI exceeded market expectations in first quarter profits and revenue, primarily due to strong demand for its heated tobacco products and ZYN nicotine pouches.

 

The flagship heated tobacco device IQOS is expected to enter the US market in the second quarter. The shipment volume of IQOS products in the first quarter was 33.1 billion, a year-on-year increase of 20.9%, compared to the previous quarter's growth rate of 6.1%.

 

PMI's smoke-free business (SFB) accounts for 39% of its total net revenue, with significant progress made in markets such as Japan and South Korea. IQOS has achieved a market share of over 29% in Japan, with increasing acceptance.

 

PMI's ZYN nicotine pouches reported strong sales performance, with canned shipment volumes increasing by 40.0% to 1.316 billion cans, a 79.7% growth compared to the same period last year. At the same time, the company also raised its forecast for shipments of nicotine pouches to the United States from an estimated 520 million cans to around 560 million cans. Net revenue organically grew by 7% to 8.5%.

 

PMI CEO Jacek Olczak stated in a press release:

 

Our strong performance in the first quarter, excellent revenue growth, and significant profit margin expansion have given us confidence to raise our currency neutral guidance for 2024. With the operational leverage of IQOS and the strong economic benefits of ZYN driving momentum in the smoke-free category, our underlying sales volume is rapidly increasing, and organic net revenue and gross profit are accelerating. In a dynamic operating environment characterized by geopolitical and economic tensions exacerbating currency fluctuations, we are executing efficiently and effectively. We are making every effort to address these challenges and achieve strong growth and value creation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 has passed final stage in the Dáil and will move to the Seanad, with measures to limit vape flavours to tobacco or unflavoured products and tighten rules on packaging colours, retail advertising, in-store displays and sales of nicotine pouches to minors.
News
Jun.26 by 2Firsts Perspectives
Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia’s Finance Minister Anwar Ibrahim said duties and taxes on nicotine-containing vape products will be determined in line with the Court of Appeal’s ruling on whether liquid or gel nicotine can be exempted from the Poisons List under the Poisons Act 1952, a case that could affect the legal basis for vape taxation, retail sales and future ban policy.
Jun.29
How AI Is Rewriting the Talent Playbook for the Nicotine Industry: JTI’s Case
How AI Is Rewriting the Talent Playbook for the Nicotine Industry: JTI’s Case
AI is moving from a back-office tool to a core organizational capability in the nicotine industry. Based on JTI’s responses, this 2Firsts feature examines how AI is reshaping talent strategy, internal mobility, decision-making and human accountability as global tobacco companies compete in the shift toward new nicotine categories.
Jun.17
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
France Bans Zyn and Other Nicotine Pouches, Violators Face Jail and Fines
France Bans Zyn and Other Nicotine Pouches, Violators Face Jail and Fines
France has officially banned nicotine pouches and other oral nicotine products, including Zyn. The new regulation classifies such products as “toxic substances” and imposes criminal penalties on their use, possession, purchase, and sale. Violators may face up to five years in prison and fines of up to €400,000 (approximately $436,600).
Regulations
May.25
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14